Sugi Predict

Sugi Predict / Compounds / Biphenyl

Biphenyl

Biphenyl

SCHEMBL30337

NCCc1ccccc1[Pd].c1ccc(-c2ccccc2)cc1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 11/20 0.52
▸ HTR2A P28223 3/20 0.48
▸ HRH1 P35367 1/20 0.44
▸ CYP2A6 P11509 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.43
▸ DPP4 P27487 1/20 0.42
▸ ADRA2C P18825 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HMGB1 P09429 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL19410947 0.98 TAAR1 (0.50) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2
SCHEMBL29687091 0.91 TAAR1 (0.56) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2
SCHEMBL2773498 0.91 TAAR1 (0.56) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2
Hydrochloric Acid SCHEMBL28271343 0.89 TAAR1 (0.54) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2
Methylene Chloride SCHEMBL20271176 0.85 TAAR1 (0.54) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2
SCHEMBL14938415 0.82 DPP4 (0.47) TAAR1HTR2ADPP4ADRA2C
SCHEMBL18769981 0.77 TAAR1 (0.50) TAAR1HTR2AHRH1
Methane SCHEMBL18770053 0.76 TAAR1 (0.44) TAAR1HTR2AHRH1
SCHEMBL1868872 0.74 DPP4 (0.68) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2
SCHEMBL224549 0.74 TAAR1 (0.70) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668863-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2020-06-24 — — EP disclosed
US-10568879-B2 Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (BE) 2020-02-25 — — US disclosed
EP-3478675-A1 HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS Janssen Pharmaceutica N.V. (BE) 2019-05-08 — — EP disclosed
US-10253040-B1 MK2 inhibitors and uses thereof CELGENE CAR LLC (BM) 2019-04-09 — — US disclosed
WO-2019036377-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2019-02-21 — — WO disclosed
WO-2018106646-A1 AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-06-14 — — WO disclosed
WO-2018002217-A1 HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-04 — — WO disclosed
EP-3233858-A1 ERK INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-25 — — EP disclosed
EP-3224258-A1 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS Genentech, Inc. (US) 2017-10-04 — — EP disclosed
EP-3174537-A1 MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN Merck Sharp & Dohme Corp. (US) 2017-06-07 — — EP disclosed
WO-2015054088-A1 3,3'-DISUBSTITUTED INDOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN MERCK SHARP & DOHME CORP. (US) 2015-04-16 — — WO disclosed
WO-2015011400-A1 NOVEL PYRROLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2015-01-29 — — WO disclosed
WO-2014210354-A1 AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2014-12-31 — — WO disclosed
WO-2014170197-A1 PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-23 — — WO disclosed
WO-2014164968-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2014-10-09 — — WO disclosed
WO-2014159559-A1 FUSED FURANS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2014-10-02 — — WO disclosed
WO-2014134774-A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY MERCK SHARP & DOHME CORP. (US) 2014-09-12 — — WO disclosed
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 — — EP disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 — — WO disclosed
WO-2010138589-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE GENENTECH, INC. (US) 2010-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10568879-B2 Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders GPR84, GPR88, GPR65 TAAR1 326/4885HTR2A 235/4885HRH1 134/4885
US-10253040-B1 MK2 inhibitors and uses thereof MKNK2, DUSP2, MKNK1 TAAR1 4475/4885HTR2A 1870/4885HRH1 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.